دورية أكاديمية
Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects
| العنوان: | Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects |
|---|---|
| المؤلفون: | Farrag, Mariam, Ait Eldjoudi, Djedjiga, González-Rodríguez, María, Cordero-Barreal, Alfonso, Ruiz-Fernández, Clara, Capuozzo, Maurizio, González-Gay Mantecón, Miguel Ángel, Mera, Antonio, Lago, Francisca, Soffar, Ahmed, Essawy, Amina, Pino, Jesus, Farrag, Yousof, Gualillo, Oreste |
| المساهمون: | Universidad de Cantabria |
| المصدر: | Frontiers in endocrinology, 2023, 13, 1101091 |
| بيانات النشر: | Frontiers Media S.A. |
| سنة النشر: | 2023 |
| المجموعة: | Universidad de Cantabria: UCrea |
| مصطلحات موضوعية: | Asprosin, Adipokines, Metabolic diseases, Obesity, Diabetes, PCOS |
| الوصف: | Adipose tissue malfunction leads to altered adipokine secretion which might consequently contribute to an array of metabolic diseases spectrum including obesity, diabetes mellitus, and cardiovascular disorders. Asprosin is a novel diabetogenic adipokine classified as a caudamin hormone protein. This adipokine is released from white adipose tissue during fasting and elicits glucogenic and orexigenic effects. Although white adipose tissue is the dominant source for this multitask adipokine, other tissues also may produce asprosin such as salivary glands, pancreatic B-cells, and cartilage. Significantly, plasma asprosin levels link to glucose metabolism, lipid profile, insulin resistance (IR), and b-cell function. Indeed, asprosin exhibits a potent role in the metabolic process, induces hepatic glucose production, and influences appetite behavior. Clinical and preclinical research showed dysregulated levels of circulating asprosin in several metabolic diseases including obesity, type 2 diabetes mellitus (T2DM), polycystic ovarian syndrome (PCOS), non-alcoholic fatty liver (NAFLD), and several types of cancer. This review provides a comprehensive overview of the asprosin role in the etiology and pathophysiological manifestations of these conditions. Asprosin could be a promising candidate for both novel pharmacological treatment strategies and diagnostic tools, although developing a better understanding of its function and signaling pathways is still needed. ; Funding: OG and FL are Staff Personnel (I3SNS Stable Researcher) of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff contract (ISCIII)/SERGAS). OG and MG-G are members of RICORS Program, RD21/0002/0025 via ISCIII and FEDER. FL is a member of Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV). The work of OG and JP (PI20/00902), and FL (PI21/01145 and CB16/11/00226) is funded by ISCIII and FEDER. OG is a beneficiary of a project funded by the Research Executive Agency of the European Union in the ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1664-2392 |
| العلاقة: | https://hdl.handle.net/10902/29839Test |
| DOI: | 10.3389/fendo.2022.1101091 |
| الإتاحة: | https://doi.org/10.3389/fendo.2022.1101091Test https://hdl.handle.net/10902/29839Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; openAccess |
| رقم الانضمام: | edsbas.4D167254 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16642392 |
|---|---|
| DOI: | 10.3389/fendo.2022.1101091 |